SCHEDULE 13G/A: Pfizer Discloses 3.6% Stake in Cardiff Oncology, Inc. via Amended Schedule 13G Filing
Beneficial Ownership Report
Pfizer Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 3.6% of Cardiff Oncology, Inc.'s common stock as of December 31, 2024.
Summary
- Pfizer Inc. reported beneficial ownership of 2,411,575 shares of Cardiff Oncology, Inc. common stock.
- This ownership represents 3.6% of Cardiff Oncology, Inc.'s total outstanding common stock.
- The percentage is calculated based on 66,524,182 shares of Common Stock outstanding, as reported in Cardiff Oncology's prospectus supplement filed on December 10, 2024.
- The event date requiring this filing was December 31, 2024.
- Pfizer Inc. holds sole voting power and sole dispositive power over all 2,411,575 shares.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of Cardiff Oncology, Inc.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. The filing itself is a factual disclosure of ownership. The positive aspect comes from a major player like Pfizer holding a stake, which can be interpreted as a positive signal for Cardiff Oncology, even if passive.
Positives
- Pfizer Inc., a globally recognized pharmaceutical company, holding a significant stake in Cardiff Oncology, Inc. could be interpreted as a positive signal, potentially indicating confidence in Cardiff Oncology's prospects or a strategic interest.
Future Outlook
The document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Cardiff Oncology's future performance or Pfizer's investment strategy beyond the current holding.
Industry Context
This filing indicates a significant, albeit passive, investment by a major pharmaceutical company (Pfizer) in a biotechnology firm (Cardiff Oncology). Such investments are common in the pharmaceutical and biotech sectors, often signaling potential strategic interest, collaboration, or simply a financial stake in a company with promising research or assets. It could suggest Pfizer sees value in Cardiff Oncology's pipeline or technology.
Comparison to Industry Standards
- This document is a standard Schedule 13G filing, which is a regulatory disclosure of beneficial ownership. It does not provide financial results or operational metrics for comparison to industry standards.
- The 3.6% stake is below the 5% threshold that would typically trigger more detailed reporting (Schedule 13D) indicating an intent to influence or control, aligning with a passive investment strategy common for institutional holders.
Stakeholder Impact
- Shareholders of Cardiff Oncology: May view Pfizer's stake as a positive signal, potentially increasing investor confidence.
- Shareholders of Pfizer: The investment represents a small, passive stake in another company, unlikely to have a material impact on Pfizer's overall financial performance.
Key Dates
| Date | Description |
|---|---|
| 2022-04-25 | Original filing date of Cardiff Oncology's effective shelf registration statement on Form S-3. |
| 2024-12-10 | Date Cardiff Oncology's prospectus supplement was filed, reporting 66,524,182 shares outstanding, which serves as the basis for the ownership percentage calculation. |
| 2024-12-31 | Date of the event which required the filing of this statement (snapshot date for beneficial ownership). |
| 2025-02-12 | Date the Schedule 13G Amendment No. 1 was signed by Pfizer Inc. |
Keywords
Pfizer Inc., Cardiff Oncology Inc., Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceutical, Biotechnology, Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.